Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 12/8/2009
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||- / -||UN / IM|
Administered by: Unknown Purchased by: Unknown
Symptoms: Arthralgia, Headache, Lymphadenopathy, Muscular weakness, Paraesthesia
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? No
Other Medications: Unknown
Preexisting Conditions: Unknown
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES0908USA05097
Write-up:Information was obtained on request by the company from the agency via a Case Line Listing through CSL NZ as part of a business agreement (Manufacturer control number: 084849), concerning a 16 year old female patient who on 27-APR-2009 was vaccinated with 0.5 ml of a dose of GARDASIL intramuscularly. On 27-APR-2009 the patient experienced paraesthesia (severe), lymphadenopathy (severe), arthralgia (severe), headache (severe) and muscle weakness (severe). At the time of reporting in June 2009, the patient''s paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness persisted. The agency considered that paraesthesia (severe), lymphadenopathy (severe), arthralgia (severe), headache (severe) and muscle weakness (severe) were "possible" related to therapy with GARDASIL. Paraesthesia (severe), lymphadenopathy (severe), arthralgia (severe), headache (severe) and muscle weakness (severe) were resulted in persisting disability. The original reporting source was not provided. Additional information is not expected.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166